HEPATOCELLULAR CANCER
Clinical trials for HEPATOCELLULAR CANCER explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CANCER trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer combo trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called TAK-500, given alone or with pembrolizumab, in 61 adults with advanced solid tumors (e.g., pancreatic, lung, breast cancer). The goal was to check safety and see if the drug shrinks tumors. The study was terminated early, so results a…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New drug cocktail targets Hard-to-Treat liver cancers
Disease control TerminatedThis study tested a combination of three drugs—nivolumab, tadalafil, and vancomycin—in adults with liver cancer or liver tumors that spread from colorectal or pancreatic cancer. The goal was to see if the treatment could shrink tumors. The trial was stopped early, but the approac…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 17:53 UTC
-
Gene mapping study aims to match GI cancer patients with tailored therapies
Knowledge-focused TerminatedThis study looked at genetic changes in tumors from 565 people with advanced cancers of the stomach, liver, bile ducts, gallbladder, or pancreas. The goal was to see how often these changes could be targeted with specific drugs and whether using genetic information helped doctors…
Matched conditions: HEPATOCELLULAR CANCER
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC